Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ)
- Previous Close
29.85 - Open
29.70 - Bid 29.87 x --
- Ask 29.88 x --
- Day's Range
29.58 - 30.10 - 52 Week Range
17.49 - 31.25 - Volume
3,462,500 - Avg. Volume
5,613,388 - Market Cap (intraday)
21.887B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
38.79 - EPS (TTM)
0.77 - Earnings Date --
- Forward Dividend & Yield 0.08 (0.27%)
- Ex-Dividend Date Jul 20, 2023
- 1y Target Est
25.94
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is based in Taiyuan, China.
www.slbiop.comRelated News
Performance Overview: 000403.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000403.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000403.SZ
Valuation Measures
Market Cap
21.89B
Enterprise Value
20.93B
Trailing P/E
38.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.55
Price/Book (mrq)
3.07
Enterprise Value/Revenue
9.15
Enterprise Value/EBITDA
32.49
Financial Highlights
Profitability and Income Statement
Profit Margin
27.07%
Return on Assets (ttm)
5.82%
Return on Equity (ttm)
9.37%
Revenue (ttm)
2.5B
Net Income Avi to Common (ttm)
677.68M
Diluted EPS (ttm)
0.77
Balance Sheet and Cash Flow
Total Cash (mrq)
1.76B
Total Debt/Equity (mrq)
7.26%
Levered Free Cash Flow (ttm)
--
Research Analysis: 000403.SZ
Company Insights: 000403.SZ
000403.SZ does not have Company Insights